Clinical trials: Type 1 Diabetes in Adolescence
- Condition Type 1 Diabetes in Adolescence
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Type 1 Diabetes Mellitus, Type2 Diabetes Mellitus
Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics
The purpose of this study is to demonstrate the performance of the Guardian™ Sensor (3) with an advanced algorithm in subjects age 2 - 80 years, for the span of 170 hours (7 days).
- Trial name
- NCT03966911
- Testing
- Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter
- Where
- 15 sites in United States
- Volunteers
- 335 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
This trial is conducted in Asia, Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of insulin degludec/insulin aspart once daily plus insulin aspart for the remaining meals in…
- Trial name
- NCT01835431
- Testing
- insulin degludec/insulin aspart, insulin aspart, insulin detemir
- Where
- 73 sites in United States, Belgium and 13 more
- Volunteers
- 362 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
The purpose of this study was to assess how glucagon administered nasally, using a nasal dosing delivery device, works in children and adolescents compared with commercially-available glucagon given by injection.
- Trial name
- NCT01997411
- Testing
- Nasal Glucagon, Intramuscular Glucagon
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes
The main objective of this study is to identify the dose of linagliptin in paediatric patients. Other efficacy objectives include the comparison of the lowering effect of linagliptin low dose, high dose and placebo on the fasting…
- Trial name
- NCT01342484
- Testing
- BI1356 low dose, BI1356 high dose
- Where
- 25 sites in United States, Canada and 7 more
- Volunteers
- 40 people
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes
Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes
The purpose of this study is to determine whether Type 1 Diabetic subjects using the Paradigm 722 System, which is a glucose sensor-augmented insulin pump, can improve glycemic control when compared to subjects using the Paradigm…
- Trial name
- STAR1 (NCT00211510)
- Testing
- Paradigm 722 sensor augmented pump, Paradigm 715 insulin pump
- Where
- 7 sites in United States
- Volunteers
- 146 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 1
MiniMed™ 670G System China Study for Type I Diabetic
The purpose of this study is to obtain clinical data in Chinese patients to support product registration of the MiniMed™ 670G system with the National Medical Product Administration (NMPA) in China.
- Trial name
- NCT04663295
- Testing
- MiniMed™ 670G system
- Where
- 4 sites in China
- Volunteers
- 74 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus
Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)
This clinical trial will explore the safety and effect of autologous ex vivo expanded polyclonal regulatory T-cells on beta cell function in patients, aged 8 to 17, with recent onset T1DM.
- Trial name
- NCT02691247
- Testing
- CLBS03 Low Dose, CLBS03 High Dose
- Where
- 15 sites in United States
- Volunteers
- 113 people
- Sponsor
- Lisata Therapeutics, Inc.
Diabetes Mellitus, Type 1
Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents
To assess the safety and efficacy of Exubera on pulmonary function and glycemic control in subjects ages 6-17 over a 1 year period.
- Trial name
- NCT00479258
- Testing
- Inhaled insulin (Exubera), Subcutaneous Insulin (subject's prescribed)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Pfizer
Type 1 Diabetes Mellitus
A Study of LY900014 in Participants With Type 1 Diabetes Mellitus
The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in participants with type 1 diabetes mellitus. There are 2 parts to this study.
- Trial name
- NCT03465878
- Testing
- LY900014, Insulin Lispro
- Where
- 2 sites in Canada, Germany
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of insulin degludec in children and adolescents with type 1 diabetes mellitus.
- Trial name
- BEGIN™ (NCT01513473)
- Testing
- insulin degludec, insulin detemir, insulin aspart
- Where
- 81 sites in United States, Bulgaria and 10 more
- Volunteers
- 350 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus
The purpose of this study is to determine the pharmacokinetic and safety profile of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
- Trial name
- NCT00957268
- Testing
- Alogliptin
- Where
- 7 sites in United States
- Volunteers
- 46 people
- Sponsor
- Takeda
Hypoglycemia, Diabetes Mellitus
Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents
Up to fifty (50) children and adolescents with type 1 diabetes (T1D) aged 4 to ˂18 years at time of enrolment will be selected for inclusion in the study.
- Trial name
- NCT02402933
- Testing
- Nasal Glucagon
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Control-IQ Technology 2.0 Adult and Adolescent Feasibility Study
The purpose of this study is to obtain preliminary safety and performance data on planned improvements to Control-IQ technology.
- Trial name
- NCT05014789
- Testing
- Control-IQ technology 2.0
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes, Diabetes Mellitus, Type 1
Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689
This trial is conducted in Europe. The aim of this research is to assess the safety of continuous treatment with insulin detemir following participation in trial NN304-1689 (NCT00435019) on antibody development.
- Trial name
- NCT00623194
- Testing
- insulin detemir, insulin aspart
- Where
- 32 sites in Bulgaria, Czechia and 9 more
- Volunteers
- 146 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in subjects age 2 - 80 years, for the span of 170 hours (7 days).
- Trial name
- NCT04436822
- Testing
- Continuous Glucose Monitoring
- Where
- 18 sites in United States, China
- Volunteers
- 317 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes, Diabetes Mellitus, Type 1
Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes
This trial is conducted in Europe. The aim of this research is to compare the efficacy and safety of treatment with NPH insulin and insulin detemir.
- Trial name
- NCT00435019
- Testing
- insulin detemir, insulin NPH, insulin aspart
- Where
- 43 sites in Bulgaria, Czechia and 9 more
- Volunteers
- 348 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes
This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of faster-acting insulin aspart compared to NovoRapid® both in combination with insulin degludec in children and adolescents with type 1…
- Trial name
- onset®7 (NCT02670915)
- Testing
- Faster-acting insulin aspart, insulin aspart, insulin degludec
- Where
- 155 sites in United States, Bulgaria and 16 more
- Volunteers
- 834 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus
Primary Objective: To compare the efficacy of a new formulation of insulin glargine (HOE901-U300) to Lantus in terms of change of HbA1c from baseline to endpoint (month 6) in children and adolescents with type 1 diabetes…
- Trial name
- EDITION JUNIOR (NCT02735044)
- Testing
- Insulin glargine,300 U/mL, Insulin glargine (100 units /mL), Background therapy
- Where
- 107 sites in United States, Argentina and 22 more
- Volunteers
- 463 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab
The purpose of this study is to determine whether teplizumab slows the loss of β cells and preserves β cell function in children and adolescent 8-17 years old who have been diagnosed with T1D in the previous 6 weeks..
- Trial name
- PROTECT (NCT03875729)
- Testing
- teplizumab
- Where
- 62 sites in United States, Belgium and 7 more
- Volunteers
- 328 people
- Sponsor
- Provention Bio, Inc.
Diabetes Mellitus, Type 1
A Study on the Effect of 2 Pen Devices on HbA1c
The purpose of this study is to test the hypothesis that the HumaPen Memoir with memory function, when used over 24 weeks for prandial insulin injections achieves superior glycemic control, when compared to the conventional…
- Trial name
- NCT00985712
- Testing
- Insulin Lispro, Huminsulin Regular, HumaPen Memoir
- Where
- 29 sites in Germany
- Volunteers
- 263 people
- Sponsor
- Eli Lilly and Company